• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    6/3/26 10:09:58 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NOTV alert in real time by email
    false 0000720154 0000720154 2026-06-02 2026-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

     

    Date of Report (Date of earliest event reported): June 2, 2026

     

    INOTIV, INC.
    (Exact name of registrant as specified in its charter)

     

    Indiana   0-23357   35-1345024
    (State or other jurisdiction of
    incorporation)
      (Commission File Number)   (IRS Employer Identification No.)

      

    2701 KENT AVENUE

    WEST LAFAYETTE, indiana

     

     

    47906-1382

    (Address of principal executive offices)   (Zip Code)

     

    Registrant's telephone number, including area code: (765) 463-4527

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

      

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange
    on which registered
    Common Shares   NOTV   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Explanatory Note

     

    Prepackaged Debt Restructuring Pursuant to Restructuring Support Agreement

     

    Inotiv, Inc. (the “Company”) and certain of its direct and indirect subsidiaries (collectively with the Company, the “Company Parties” or the “Debtors”), intend to implement a comprehensive restructuring of the Company’s debt obligations and capital structure (the “Restructuring”) in accordance with a Restructuring Support Agreement (as defined below) with certain of its key creditors. The Restructuring is expected to reduce the Company’s total funded debt obligations by approximately $326 million through a conversion of a substantial portion of the Company’s funded debt obligations into equity of the reorganized Company, and to reduce the Company’s annual cash interest expense by providing the Company with a simplified capital structure on the Plan Effective Date. In connection with the Restructuring, the Company will also obtain a debtor-in-possession financing facility to fund operations during the pendency of the Chapter 11 Cases, which will be rolled into a first lien exit financing facility upon emergence.

     

    The Restructuring Support Agreement contemplates implementing the Restructuring through a consensual, joint prepackaged plan of reorganization (the “Plan”) of the Company Parties in voluntary cases (the “Chapter 11 Cases”) filed on June 3, 2026 (the “Petition Date”) pursuant to chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”). Holders of substantial majorities of the Company’s prepetition first lien loans, second lien PIK notes, and unsecured convertible notes, have all entered into the Restructuring Support Agreement agreeing to support the Restructuring, and voted in favor of the Restructuring and the Plan substantially contemporaneously with signing the Restructuring Support Agreement as part of the Company Parties’ prepetition solicitation of votes on the Plan. The Company does not expect any adverse operational impact from the Restructuring and plans to continue to operate and pay vendors and employees in the ordinary course of business as “debtors in possession” under the jurisdiction of the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Company expects to emerge from the Chapter 11 Cases as a private company within 50 days.

     

    Capitalized terms used but not defined herein have the meanings given to them in the Restructuring Support Agreement and the term sheet attached thereto as Exhibit B (the “Restructuring Term Sheet”).

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    Restructuring Support Agreement

     

    On June 2 2026, the Company entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the “Restructuring Support Agreement”) with:

     

    ·certain lenders, or investment advisors, or holders of claims pursuant to the Company’s obligations under that certain credit agreement, dated as of November 5, 2021, between the Company, as borrower, the guarantors and lenders party thereto, and Acquiom Agency Services LLC, as successor administrative agent and collateral agent (as amended, the “Prepetition First Lien Credit Agreement,” and such lenders, advisors, or managers who are party to the Restructuring Support Agreement, the “Consenting First Lien Lenders”);

     

    ·certain holders, or investment advisors, sub-advisors, or managers for the accounts of beneficial holders or beneficial holders (which such accounts or beneficial holders such investment advisors, sub-advisors, or managers have authority to bind or direct) of the Company’s 15.00% Senior Secured Second Lien PIK Notes due 2027 issued under that certain indenture, dated as of September 13, 2024, by and between the Company, as issuer, and U.S. Bank Trust Company, National Association, as trustee and notes collateral agent (the “Prepetition PIK Notes Indenture,” and such holders, advisors, or managers who are party to the Restructuring Support Agreement, the “Consenting PIK Noteholders”); and

     

    2 

     

     

    ·certain holders, or investment advisors, sub-advisors, or managers for the accounts of beneficial holders or beneficial holders (which such accounts or beneficial holders such investment advisors, sub-advisors, or managers have authority to bind or direct) of the Company’s 3.25% Convertible Senior Notes due 2027 issued under that certain indenture, dated as of September 27, 2021, by and between Inotiv, Inc., as issuer, the guarantor party thereto, and U.S. Bank Trust Company, National Association, as trustee (the “Prepetition Convertible Unsecured Notes Indenture,” and such holders, advisors, or managers who are party to the Restructuring Support Agreement, the “Consenting Unsecured Convertible Noteholders,” and together with the Consenting First Lien Lenders and the Consenting PIK Noteholders, the “Consenting Stakeholders”).

     

    The Restructuring Support Agreement provides for the Restructuring to be effectuated through the Plan, a copy of which is furnished as part of Exhibit 99.1 hereto, and the specific terms underlying the Restructuring Support Agreement are further detailed in the Plan.

     

    Commitments and Representations. The Company and the Consenting Stakeholders have made certain customary commitments and representations in the Restructuring Support Agreement, including, among other things, to support and take all commercially reasonable actions reasonably necessary to facilitate the transactions contemplated by the Restructuring Support Agreement. Specifically, the Consenting Stakeholders have committed to the Company, among other things, to support and vote for the Plan.

     

    Milestones. The Restructuring Support Agreement contains certain milestones (“Milestones”) relating to the progress of the anticipated Chapter 11 Cases, which include, among other things, commencement of the Chapter 11 Cases no later than June 3, 2026 (the “Petition Date”), entry of an interim order by the Bankruptcy Court authorizing the Debtors’ use of cash collateral and the DIP Facility and entry of a case scheduling order no later than three (3) days following the Petition Date, entry of a final order by the Bankruptcy Court authorizing the Debtors’ use of cash collateral and the DIP Facility on a final basis and entry of the confirmation order no later than 45 days following the Petition Date, and the occurrence of the date on which the Plan has become effective in accordance with its terms (the “Plan Effective Date”) no later than 50 days following the Petition Date.

     

    Summary of Material Terms. The material terms of the Plan, subject to Bankruptcy Court approval, include, among other things:

     

    ·DIP Facility. In connection with the Chapter 11 Cases, the Consenting First Lien Lenders will provide the Company with a debtor-in-possession financing facility in an aggregate amount of $65.4 million (the “DIP Facility”), consisting of (a) $25 million in new money senior secured superpriority term loans, and (b) a $40.4 million roll-up of outstanding delayed draw term loans under the Company’s prepetition bridge facility. The DIP Facility will bear interest at either, at the Company’s election, SOFR plus 9.00% or Alternate Base Rate plus 8.00% and will mature 90 days following the Petition Date, subject to further extension with the consent of the required DIP lenders.

     

    ·Exit Term Loan Facility. On the Plan Effective Date, the reorganized Debtors are expected to enter into a senior secured first lien exit term loan facility (the “Exit Term Loan Facility”) in an aggregate principal amount of up to $150 million (including paid-in-kind interest, fees, original issue discount, and premiums). All outstanding DIP obligations are expected to be converted dollar-for-dollar into exit term loans under the Exit Term Loan Facility.

     

    ·Prepetition First Lien Claims. Holders of allowed prepetition first lien claims are expected to receive, in full and final satisfaction of such claims, their pro rata share of (a) 93% of the new equity interests to be issued by the reorganized Company on the Plan Effective Date (the “New Equity Interests”), subject to dilution on account of the New Warrants (as defined below) and the Management Incentive Plan (as defined below), and (b) the remaining exit term loans under the Exit Term Loan Facility (i.e., exit term loans that were not provided to the DIP lenders in satisfaction of the DIP claims).

     

    ·Prepetition PIK Notes Claims. Holders of allowed prepetition PIK notes claims are expected to receive, in full and final satisfaction of such claims, their pro rata share of 21% of (a) 7% of the New Equity Interests, subject to dilution on account of the New Warrants and the Management Incentive Plan, and (b) the New Warrants (defined below) ((a) and (b) collectively, the “Notes Recovery”).

     

    ·Prepetition Unsecured Convertible Notes Claims. Holders of allowed prepetition unsecured convertible notes claims are expected to receive, in full and final satisfaction of such claims, their pro rata share of 79% of the Notes Recovery.

     

    3 

     

     

    ·DOJ Claims. The claims of the United States Department of Justice arising under that certain Plea Agreement, dated June 3, 2024 (the “DOJ Claims”), are expected to be allowed and reinstated on the Plan Effective Date.

     

    ·General Unsecured Claims. Each holder of an allowed general unsecured claim is expected to have such claim reinstated, or to otherwise receive treatment rendering such claim unimpaired pursuant to section 1124 of the Bankruptcy Code.

     

    ·Section 510(b) Claims. All Section 510(b) claims, including claims arising from the purchase or sale of securities of any Debtor, are expected to be discharged and released on the Plan Effective Date, and holders thereof shall not receive or retain any distribution on account of such claims.

     

    ·Existing Equity Interests. On the Plan Effective Date, all existing equity interests in the Company will be cancelled, released, and extinguished without any distribution, and holders of existing equity interests shall not receive or retain any distribution, property, or other value on account of such interests.

     

    ·New Equity Interests and New Warrants. On the Plan Effective Date, the reorganized Company is expected to issue a single class of New Equity Interests, and new warrants exercisable into New Equity Interests representing 11% of New Equity Interests issued on the Plan Effective Date, in the aggregate, on a fully diluted basis (subject to dilution by the Management Incentive Plan) (the “New Warrants”). The New Warrants will have a strike price equal to an implied share price using a post-transaction enterprise value of $350 million and a four-year exercise period following the Plan Effective Date.

     

    ·Management Incentive Plan. The new board of directors of the reorganized Company (the “New Board”) may implement a management incentive plan pursuant to which equity-based awards for up to 10% of the New Equity Interests of the reorganized Company, on a fully diluted basis (assuming the New Warrants are treated as having been fully exercised), may be made available to the Company’s employees and directors (the “Management Incentive Plan”).

     

    Termination. Each of the parties to the Restructuring Support Agreement may terminate the agreement under certain circumstances and subject to the terms set forth therein, including, among other things: (i) in the case of the Consenting Stakeholders, (a) the failure of the Company to meet a Milestone or achieve the Plan Effective Date before the applicable outside date; or (b) if the Company seeks or obtains an order of the Bankruptcy Court authorizing the rejection of the Restructuring Support Agreement; (ii) the occurrence of certain breaches of the Restructuring Support Agreement; (iii) the mutual agreement of the parties; and (iv) in the case of the Company, if the board of directors, board of managers, or such similar governing body of the Company reasonably determines in good faith after consultation with outside counsel that proceeding with any of the transactions under the Restructuring Support Agreement would be inconsistent with the exercise of its fiduciary duties under applicable law.

     

    Consummation. Consummation of the transactions contemplated by the Restructuring Support Agreement is subject to, among other things, approval of the Plan by the Bankruptcy Court. Accordingly, no assurance can be given that the transactions described therein will be consummated.

     

    The foregoing description of the Restructuring Support Agreement is not complete and is qualified in its entirety by reference to the Restructuring Support Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference. The representations, warranties and covenants contained in the Restructuring Support Agreement have been made solely for the purpose of such agreement and as of specific dates, for the benefit of the parties thereto. In addition, such representations, warranties and covenants (i) may have been qualified by confidential disclosures exchanged between the parties, (ii) are subject to materiality qualifications contained in such agreement which may differ from what may be viewed as material by investors, and (iii) have been included in such agreement for the purpose of allocating risk between the contracting parties rather than establishing matters of fact. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of actual facts or circumstances, and the subject matter of representations and warranties may change after the date as of which such representations or warranties were made. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Restructuring Support Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

     

    4 

     

     

    Item 1.03. Bankruptcy or Receivership.

     

    On June 3, 2026 (i.e., the Petition Date), the Company Parties filed voluntary petitions to commence the Chapter 11 Cases in the Bankruptcy Court to implement the Plan effectuating the Restructuring in accordance with the Restructuring Support Agreement. Prior to commencing the Chapter 11 Cases, the Company commenced the solicitation of the Plan (the “Solicitation”) with a related disclosure statement (the “Disclosure Statement”). The Company has requested that the Bankruptcy Court administer the Chapter 11 Cases jointly for administrative purposes only under the caption In re Inotiv, Inc., et al.

     

    The Company Parties continue to operate their business as debtors-in-possession under the jurisdiction of the Bankruptcy Court in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Company Parties have filed with the Bankruptcy Court customary motions seeking “first day” relief intended to ensure the Company Parties’ ability to continue their ordinary course operations during the Chapter 11 Cases, including the authority to obtain postpetition financing under the DIP Facility, use cash collateral, pay employee wages and benefits and vendors and suppliers in the ordinary course of business, and other customary operational and administrative relief.

     

    Item 2.04. Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement.

     

    The filing of the Chapter 11 Cases constitutes an event of default that accelerated the Company’s obligations under the following instruments (the “Debt Instruments”):

     

    ·the Prepetition First Lien Credit Agreement;

     

    ·the Prepetition PIK Notes Indenture; and

     

    ·the Prepetition Convertible Unsecured Notes Indenture.

     

    The Debt Instruments provide that as a result of the Chapter 11 Cases, the principal and interest, and, if applicable, premiums, due thereunder shall be immediately due and payable. Any efforts to enforce such payment obligations under the Debt Instruments are automatically stayed as a result of the Chapter 11 Cases, and the creditors’ rights of enforcement in respect of the Debt Instruments are subject to the applicable provisions of the Bankruptcy Code.

     

    Item 7.01. Regulation FD Disclosure.

     

    Commencement of Solicitation

     

    Pursuant to the Restructuring Support Agreement, on June 2, 2026, and prior to filing the Chapter 11 Cases, the Company Parties commenced the Solicitation, including by distributing the Disclosure Statement and other solicitation materials to certain eligible holders of claims against the Company Parties that are entitled to vote on the Plan. A copy of the Disclosure Statement (including the Plan and certain other exhibits attached thereto) is furnished as Exhibit 99.1 hereto.

     

    This Current Report on Form 8-K does not constitute an offer to sell or buy, nor the solicitation of an offer to sell or buy, any securities referred to herein, nor is this Current Report a solicitation of consents to or votes to accept the Plan. Any solicitation or offer will only be made pursuant to the Disclosure Statement (as may be amended) and only to such persons and in such jurisdictions as is permitted under applicable law, and in compliance with all applicable securities laws and provisions of the Bankruptcy Code.

     

    5 

     

     

    Press Release

     

    On June 3, 2026, the Company issued a press release announcing the Company’s entry into the Restructuring Support Agreement, commencement of the Solicitation, and filing of the Chapter 11 Cases. A copy of the press release is furnished as Exhibit 99.2 hereto.

     

    Additional Information on the Chapter 11 Cases

     

    Additional information about the Chapter 11 Cases, including access to Bankruptcy Court documents, is available online at https://restructuring.ra.kroll.com/Inotiv, a website administered by the Debtors’ claims and noticing agent, Kroll Restructuring Administration LLC (“Kroll”). Information may also be obtained by contacting Kroll by calling (844) 408-3698 (U.S./Canada, toll-free) or +1 (646) 825-3849 (international), by emailing InotivInfo@ra.kroll.com, or by writing to Inotiv, Inc., c/o Kroll Restructuring Administration LLC, 850 Third Avenue, Suite 412, Brooklyn, NY 11232.

     

    The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

     

    Item 8.01. Other Events.

     

    Cautionary Note Regarding the Company’s Securities

     

    The Company cautions that trading in its securities (including its Common Shares) during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for these securities may bear little or no relationship to the actual recovery, if any, by the holders of the Company’s securities in the Chapter 11 Cases. The Company expects that holders of its existing equity interests could experience a total loss on their investment, as the Plan contemplates that all existing equity interests in the Company will be cancelled without any distribution to existing equity holders.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)            Exhibits

     

      Exhibit
    No.
      Description
           
      10.1   Restructuring Support Agreement, dated as of June 2, 2026, by and among the Company Parties, the Consenting First Lien Lenders, the Consenting PIK Noteholders, and the Consenting Unsecured Convertible Noteholders.
           
      99.1   Disclosure Statement, dated as of June 3, 2026.
           
      99.2   Press Release, dated as of June 3, 2026
           
      104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    6 

     

     

    Cautionary Note Regarding Forward-Looking Statements

     

    Certain statements contained in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are predictive in nature and are identified generally by the use of the terms “could,” “will,” “may,” “expect,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “project,” “potential,” “continue” and similar words or expressions indicating possible future expectations, events or actions. Forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company’s business and its industry, and are not guarantees of future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein.

     

    All statements in this Current Report on Form 8-K that are not historical are forward-looking statements, including statements regarding the timing and implementation of the transactions contemplated by the Restructuring Support Agreement, the intent to solicit approval of the Plan, the Company’s ability to continue operating in the ordinary course, and the potential benefits of the Restructuring, including the Company’s ability to emerge from the Chapter 11 Cases as a private company.

     

    Such risks and uncertainties include, among other things, risks attendant to the bankruptcy process, including the Company’s ability to obtain court approval from the Bankruptcy Court with respect to motions or other requests made to the Bankruptcy Court throughout the course of the Chapter 11 Cases; the ability of the Company to consummate the Plan; the effects of the Chapter 11 Cases, including increased legal and other professional costs necessary to execute the Company’s reorganization, on the Company’s liquidity (including the availability of operating capital during the pendency of the Chapter 11 Cases), results of operations or business prospects; the effects of the Chapter 11 Cases on the interests of various constituents and the Company’s relationships with its vendors, customers, employees, and other stakeholders; the length of time that the Company will operate under Chapter 11 protection; risks associated with third-party motions in the Chapter 11 Cases; Bankruptcy Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general; the Company’s ability to satisfy the conditions and milestones in the Restructuring Support Agreement; the Company’s ability to obtain the DIP Facility on the terms described herein; changes in the Company’s ability to meet its financial obligations during the Chapter 11 Cases; the actions and decisions of creditors, regulators, and other third parties that have an interest in the Chapter 11 Cases; and other factors described in the “Risk Factors” sections of the Company’s most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

     

    Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update those statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments.

     

    7 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        INOTIV, INC.
           
    Date: June 3, 2026 By: /s/ Beth Taylor
         

    Beth Taylor

    Chief Financial Officer,

          Executive Vice President

     

     

    Get the next $NOTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOTV

    DatePrice TargetRatingAnalyst
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    2/9/2024$3.00 → $11.50Hold → Buy
    Jefferies
    7/20/2023$9.00Overweight
    Wells Fargo
    1/19/2023$10.00 → $8.00Buy → Hold
    Jefferies
    1/11/2023$4.00 → $10.00Hold → Buy
    Lake Street
    11/18/2022$60.00 → $7.00Buy → Hold
    Lake Street
    10/4/2022$27.00Buy
    Jefferies
    1/31/2022$60.00Buy
    Lake Street
    More analyst ratings

    $NOTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/23/24 9:47:13 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/12/24 6:46:46 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/10/24 4:13:30 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inotiv downgraded by Jefferies with a new price target

    Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously

    5/14/24 8:01:45 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv upgraded by Jefferies with a new price target

    Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously

    2/9/24 6:17:55 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Wells Fargo initiated coverage on Inotiv with a new price target

    Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00

    7/20/23 7:55:03 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

    Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company's existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement ("RSA") with

    6/3/26 6:15:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Provides Notice Regarding Cybersecurity Incident

    WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that perso

    2/13/26 4:30:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    SEC Filings

    View All

    Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Inotiv, Inc. (0000720154) (Filer)

    6/3/26 10:09:58 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Inotiv, Inc. (0000720154) (Filer)

    6/1/26 7:34:27 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Leadership Update, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Inotiv, Inc. (0000720154) (Filer)

    5/18/26 8:17:48 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Young John T. Jr.

    3 - Inotiv, Inc. (0000720154) (Issuer)

    5/19/26 4:20:58 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Davis Eugene I

    3 - Inotiv, Inc. (0000720154) (Issuer)

    5/19/26 4:19:33 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Financial Officer Taylor Beth A. sold $846 worth of shares (2,888 units at $0.29), decreasing direct ownership by 2% to 145,480 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    2/19/26 4:41:21 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Leadership Updates

    Live Leadership Updates

    View All

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. Announces Changes to its Board Composition

    WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic

    10/16/23 8:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Financials

    Live finance-specific insights

    View All

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co

    2/4/26 6:30:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

    –  Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million–  Fiscal 2025 revenue increased 4.5% to $513.0 million–  Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million–  Fiscal 2025 operating loss decreased 64.2% to $30.9 million–  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2025") ended September 30, 2025, and twelve mo

    12/3/25 4:05:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    4/3/24 10:47:10 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    10/6/22 12:24:15 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    9/20/22 9:00:08 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care